Neurosense Therapeutics Ltd(NRSN)

POST0.84000.02+2.31%19:54 EDT

0.8210+0.0179+2.23%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- NeuroSense prices $600,000 private placement at $0.8 per share
  Reuters · 04-29 02:30
  NeuroSense prices $600,000 private placement at $0.8 per share
- Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)
  TIPRANKS · 04-27
  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)
- NeuroSense announces departure of Chief Medical Officer
  TIPRANKS · 04-27
  NeuroSense announces departure of Chief Medical Officer
- NeuroSense CMO Ferenc Tracik steps down, effective April 27
  Reuters · 04-24
  NeuroSense CMO Ferenc Tracik steps down, effective April 27
- NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
  Reuters · 04-06
  NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
- NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
  Reuters · 04-03
  NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
- Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM
  TIPRANKS · 04-02
  Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM
- NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership
  Reuters · 04-02
  NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership
- NeuroSense FY25 net loss widens 9% to USD 11.1 million
  Reuters · 04-01
  NeuroSense FY25 net loss widens 9% to USD 11.1 million
- NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement
  Reuters · 04-01
  NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement
- Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise
  Reuters · 03-31
  Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise
- BRIEF-NeuroSense Therapeutics FY EPS USD -0.44
  Reuters · 03-31
  BRIEF-NeuroSense Therapeutics FY EPS USD -0.44
- Neurosense Therapeutics FY Operating Income USD -11.085 Million
  THOMSON REUTERS · 03-31
  Neurosense Therapeutics FY Operating Income USD -11.085 Million
- Neurosense Therapeutics FY EPS USD -0.44
  THOMSON REUTERS · 03-31
  Neurosense Therapeutics FY EPS USD -0.44
- Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
  Dow Jones · 03-31
  Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
- NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership
  Reuters · 03-31
  NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership
- NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement
  Reuters · 03-30
  NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement
- NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
  Reuters · 03-24
  NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks
- NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement
  Reuters · 03-19
  NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement
- NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement
  Reuters · 03-19
  NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement
Company Profile
Company Name
Neurosense Therapeutics Ltd
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.neurosense-tx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- 03-31
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-11-25
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-08-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-07
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-01-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-06
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-09
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-19
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-05-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-05-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-10
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-04-04
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

0.8400

Open

0.8190

Volume%

1.40

Low

0.8101

0.8031

T/O Rate

0.92%

To The Moon

Neurosense Therapeutics Ltd(NRSN)

Company Profile

Most Discussed